TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1717206
Drug: balanced amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: balanced amino acid solution (24% BCAA)
Study: 6184569
Drug: Verapamil (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (160 mg thrice daily)
Study: 6184569
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg slow release twice daily)
Study: 23841976
Drug: Kinesio Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Tape applied to hand and forearm for 6 days in combination with standard therapy
Study: 21349365
Drug: Trivalent Inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent Inactivated Vaccine (TIV)
Study: 21349365
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of TIV
Study: 19307354
Drug: Intravenous cloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cloxacillin for 6 weeks plus 2 weeks orally (p.o.)
Study: 19307354
Drug: Oral rifampin‐cotrimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rifampin‐cotrimoxazole for 8 weeks p.o.
Study: 19307354
Drug: Oral rifampin‐cotrimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rifampin‐cotrimoxazole
Study: 17325405
Drug: Lay‐led self
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lay‐led self care support group (6‐weekly sessions to teach self care skills)
Study: 15038927
Drug: Evidence-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatment
Study: 15038927
Drug: Adjunctive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapies and combination medications
Study: 11351771
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (LP) combined with insulin lispro protamine suspension (NPL)
Study: 11351771
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (HR) combined with human NPH insulin (NPH)
Study: 9684796
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose TNFR:Fc (10 mg/m2 i.v., n = 6)
Study: 9684796
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose TNFR:Fc (60 mg/m2 i.v., n = 6)
Study: 7802318
Drug: Combined anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined anesthesia based on NLA agents and placebo (simulated transcerebral electropulse exposure), n = 14
Study: 2657207
Drug: Chlorophyllypt (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorophyllypt (0.25% solution in physiological sodium chloride solution administered by intravenous drip)
Study: 2657207
Drug: Traditional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional antibiotic therapy
Study: 2657207
Drug: Broad-action antibiotics
Normalized name: broad leaved paperbark pollen extract
DrugBank: Melaleuca quinquenervia pollen (DB10478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-action antibiotics
Study: 29432877
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D and probiotic co-supplementation (50,000 IU vitamin D every 2 weeks plus 8 × 10^9 CFU/g probiotic)
Study: 27473162
Drug: Anterior approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior approach ISB with 15 ml of ropivacaine 1%
Study: 27473162
Drug: Posterior approach
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior approach ISB with 15 ml of ropivacaine 1%
Study: 20887495
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily of pyridoxine
Study: 20887495
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily of pyridoxine
Study: 15702341
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (24-week program, twice per week, consisting of calf-rise and leg-press exercises at 75% of three-repetition maximum)
Study: 2107994
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (SA)
Study: 30843263
Drug: Imipramine 50
Normalized name: trimipramine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 50 mg
Study: 30379634
Drug: Traditional Prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Prolonged Exposure Therapy
Study: 23657721
Drug: Control (10-cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10-cc syringe)
Study: 22004306
Drug: 8-session facilitated
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-session facilitated group cognitive behavioral therapy-based intervention
Study: 10052670
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (400 mcg)
Study: 7973119
Drug: Methazolamide treatment
Normalized name: Methazolamide
DrugBank: Methazolamide (DB00703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methazolamide treatment
Study: 21564160
Drug: Terutroban 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban 2.5 mg
Study: 21564160
Drug: Terutroban 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban 5 mg
Study: 21564160
Drug: Terutroban 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban 10 mg
Study: 19232204
Drug: Non-fractionated Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fractionated Heparin (NFH)
Study: 17348237
Drug: Zhong tong'an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhong tong'an combined with dexamethasone tablets
Study: 17348237
Drug: Dexamethasone tablets
Normalized name: Dexamethasone Tablets
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets alone
Study: 15087602
Drug: Placebo bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus and infusion
Study: 9172024
Drug: sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual buprenorphine 0.2 mg
Study: 9172024
Drug: oral controlled
Normalized name: Afeditab CR Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral controlled release morphine 10 mg
Study: 9172024
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (10 ml) wound infiltration
Study: 7712621
Drug: Pentoxifylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (600 mg daily for 5 days) + Aspirin (150 mg daily)
Study: 7712621
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Aspirin (150 mg daily)
Study: 3438581
Drug: Sustained theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained theophylline administration
Study: 26683453
Drug: Daily positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily positive affect among nonstudents
Study: 26683453
Drug: Daily negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily negative affect among nonstudents
Study: 26683453
Drug: Daily negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily negative affect among college students
Study: 15895316
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration arginine aspartate (5.7 g arginine and 8.7 g aspartate)
Study: 15895316
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration arginine aspartate (2.8 g arginine and 2.2 g aspartate)
Study: 3169046
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (Verapamil and Diltiazem)
Study: 26795448
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and supervised exercise (MTEX)
Study: 24041131
Drug: Combined buprenorphine-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined buprenorphine-naloxone and behavioral treatment
Study: 22858452
Drug: Prednisolone at
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone at a dose of 2 mg/kg/day (first group: 40 attacks)
Study: 22858452
Drug: Prednisolone at
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone at a dose of 0.5 mg/kg/day (second group: 46 attacks)
Study: 22858452
Drug: Prednisolone at
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone at a dose of 0.5 mg/kg/day (second group)
Study: 12003482
Drug: Braun Oral-B
Normalized name: bran Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral-B Battery toothbrush (D4)
Study: 16163912
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (Group 2)
Study: 16163912
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (Group 3)
Study: 10583311
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17beta-oestradiol daily
Study: 8582471
Drug: Dexibuprofen 400
Normalized name: Dexibuprofen 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 400 mg tablet formulation
Study: 8582471
Drug: Dexibuprofen 200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 200, 400, and 600 mg
Study: 8582471
Drug: Ibuprofen racemate
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen racemate 400, 800, and 1200 mg
Study: 2118408
Drug: BCAA-enriched TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA-enriched TPN (0.56 g BCAA kg‐1 body-weight, 50.2% BCAA)
Study: 2118408
Drug: Standard TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TPN (0.18 g BCAA kg‐1 body-weight, 15.6% BCAA)
Study: 29028762
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of morphine and midazolam
Study: 29028762
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing only
Study: 27567239
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis plus mechanical thrombectomy (IVTMT group)
Study: 27567239
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis alone (IVT group)
Study: 20864406
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of imatinib treatment
Study: 20864406
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of imatinib treatment
Study: 15812075
Drug: Maintenance vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance vinorelbine (25 mg/m²/week for 6 months)
Study: 10759821
Drug: 5% 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5‐FU in a PC vehicle (cream A)
Study: 10759821
Drug: 5% 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5‐FU in a petrolatum base (cream B)
Study: 9322481
Drug: Chlorzoxazone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorzoxazone (500 mg orally on the morning of surgery)
Study: 9322481
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no chlorzoxazone administration)
Study: 3781021
Drug: Low-dose bromocriptine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bromocriptine (1.25 to 2.5 mg) at bedtime for the first 18 days of the cycle (Group A)
Study: 3781021
Drug: Pyridoxine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (100 mg continuously) (Group B)
Study: 20156908
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg) plus Lapatinib (1,500 mg)
Study: 20156908
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg) plus Placebo
Study: 18577934
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg daily
Study: 18577934
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antidepressants with transcranial electrostimulation
Study: 11450419
Drug: One-stage cylindrical
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage cylindrical screw implants with a synthetic bone substitute
Study: 11450419
Drug: Hollow screw-type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hollow screw-type implants
Study: 11450419
Drug: Solid screw-type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid screw-type implants
Study: 11450419
Drug: One-stage implant
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage implant osseointegration with synthetic graft material
Study: 3043555
Drug: Ceruletide (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceruletide (0.8 micrograms/kg, intramuscular injections, once weekly for 4 weeks)
Study: 3043555
Drug: Placebo (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular injections, once weekly for 4 weeks)
Study: 8230622
Drug: Active antiarrhythmic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antiarrhythmic drug therapy (encainide, flecainide, moricizine)
Study: 681543
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose marihuana
Study: 681543
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose marihuana
Study: 25572623
Drug: Perception of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perception of preceptors as excellent role models in tobacco treatment
Study: 25572623
Drug: Observation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation of tobacco treatment
Study: 23228172
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily)
Study: 17132719
Drug: Full-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose cyclophosphamide (3.3 g/m2)
Study: 17132719
Drug: Half-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose cyclophosphamide (1.65 g/m2)
Study: 15529609
Drug: Diosmectite 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmectite 3 g b.i.d.
Study: 15529609
Drug: Loperamide 2
Normalized name: loperamide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 2 mg b.i.d.
Study: 11167469
Drug: Midazolam 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.025 mg x kg(‐1)
Study: 11167469
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg x kg(‐1)
Study: 9596231
Drug: General wards
Approvals — FDA: no, EMA: no, PMDA: no
Description: General wards treatment
Study: 2073105
Drug: Cefprozil 15
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil 15 mg/kg
Study: 7811050
Drug: Cefprozil 20
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil 20 mg/kg
Study: 3293253
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy combined with indomethacin at a daily dose of 75-100 mg
Study: 31989965
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (massage and exercises)
Study: 21112904
Drug: Combined aerobic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined aerobic and strength training (twice a week for 20 weeks)
Study: 19440326
Drug: Early ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early ART (initiated within 14 days of starting acute OI treatment)
Study: 19440326
Drug: Deferred ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred ART (initiated after acute OI treatment is completed)
Study: 16477653
Drug: Vt =
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vt = 5 ml/kg
Study: 16477653
Drug: Vt =
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vt = 3 ml/kg
Study: 11800144
Drug: 30mg acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg acitretin daily
Study: 9483596
Drug: suxamethonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1.0 mg.kg‐1
Study: 7848890
Drug: IV vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV vinorelbine (30 mg/m2 weekly)
Study: 3184107
Drug: Thrice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice daily hydrocortisone replacement
Study: 3184107
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily hydrocortisone replacement
Study: 26387934
Drug: Oocyte retrieval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oocyte retrieval at 36 hours post-HCG administration (n = 78)
Study: 26387934
Drug: Oocyte retrieval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oocyte retrieval at 38 hours post-HCG administration (n = 78)
Study: 15257791
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg loading dose of beta-artemether
Study: 15257791
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg loading dose of beta-artemether
Study: 11567707
Drug: Chemoprevention treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoprevention treatment trials
Study: 8465173
Drug: Toluene exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toluene exposure at 2 mg.min-1 for 3 hours
Study: 8465173
Drug: Toluene exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toluene exposure at 6 mg.min-1 for 30 minutes
Study: 8465173
Drug: Ethanol ingestion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol ingestion at 0.08 g.kg-1 during toluene exposure at 2 mg.min-1
Study: 8465173
Drug: Ethanol ingestion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol ingestion at 0.16 g.kg-1 during toluene exposure at 2 mg.min-1
Study: 8465173
Drug: Ethanol ingestion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol ingestion at 0.32 g.kg-1 during toluene exposure at 2 mg.min-1
Study: 7870932
Drug: Ethanol administration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol administration
Study: 29885163
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D along with metformin
Study: 19505384
Drug: Aerosol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol treatment with thiamphenicol glycinate acetylcysteinate (250 mg/day in 2 administrations) plus beclomethasone (400 microg/day in 2 administrations) for 10 days/month over a period of 6 months.
Study: 19505384
Drug: Aerosol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol treatment with thiamphenicol glycinate acetylcysteinate plus beclomethasone.
Study: 17126337
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone (300 mg daily for 6 weeks)
Study: 17126337
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone (30 mg daily for 6 weeks)
Study: 7619569
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment (dry powder inhalations of either salbutamol 1600 micrograms or ipratropium bromide 160 micrograms daily)
Study: 7619569
Drug: On demand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On demand treatment (only during exacerbations or periods of dyspnoea)
Study: 25237669
Drug: 11-mm implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-mm implant combined with maxillary sinus floor elevation surgery
Study: 25237669
Drug: 6-mm implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mm implant without any grafting
Study: 18191521
Drug: Late-switch group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-switch group received liposomal AmB only when sCr increase was >=100% or sCr reached 170mumol/L
Study: 15812080
Drug: Concurrent cisplatin-radiotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin-radiotherapy (CRT)
Study: 10635419
Drug: Co-amoxiclav (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (625 mg thrice daily for 10 days)
Study: 7926531
Drug: Low-osmolality, nonionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-osmolality, nonionic contrast agent (Omnipaque 300; iohexol, 672 mOsm/kg H2O)
Study: 7926531
Drug: High-osmolality, ionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-osmolality, ionic contrast agent (Hypaque 50%; diatrizoate sodium, 1515 mOsm/kg H20)
Study: 795256
Drug: Cimetidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (0.8 g daily)
Study: 30790446
Drug: Rosuvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin treatment for 6 months
Study: 28641582
Drug: IV levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV levetiracetam infusion (40 mg/kg over 5 min)